Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerOpenAI sign Language
VIPCreated with Sketch.

Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018.

Olivier Bylicki,Pascale Tomasini,Gervais Radj,Florian Guisier,Isabelle Monnet,Charles Ricordel,Laurence Bigay-Game,Margaux Geier,Christos Chouaid,Catherine Daniel,Aurelie Swalduz,Anne-Claire Toffart,Helene Doubre,Jean-Michel Peloni,Diane Moreau,Fabien Subtil,Jean-Michel Grellard,Marie Castera,Benedicte Clarisse, Pedro-Henrique. Martins-Lavinas,Chantal Decroisette, Laurent Greillier

European journal of cancer (Oxford, England : 1990)（2023）

Cited 7|Views61
No score
Abstract
Combination approach with atezolizumab with or without bevacizumab and platinum-pemetrexed achieved promising activity in metastatic EGFR-mutated or ALK/ROS1-rearranged NSCLC after tyrosine kinase inhibitor failure, with acceptable safety profile.
More
Translated text
Key words
EGFR-mutation,Immunotherapy,Non-small cell lung cancer,Resistance
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined